Skip to main content
. 1999 Dec 15;104(12):1715–1722. doi: 10.1172/JCI8082

Figure 2.

Figure 2

Anti–asialo GM1 antibodies prolong skin allograft survival in B6 recipients treated with combined CD40/CD28 blockade. B6 recipients of Balb/c skin allografts treated with anti-CD40L, CTLA4-Ig (500 μg on days 0, 2, 4, and 6) and anti–asialo GM1 (50 μL on days 0, 4, 8, and 12) (MST 86 days; n = 7) had significantly prolonged graft survival compared with recipients treated with costimulation blockade alone (MST 20 days; n = 7; P < 0.01). Recipients treated with anti–asialo GM1 alone (MST 11 days; n = 7) did not have prolonged graft survival compared with control-treated (Rabbit IgG-treated) recipients (MST 10 days; n = 7).